Real-World Experience of Clascoterone Cream 1% in Acne Management: Case Series and Canadian Experience

This case series from a Canadian dermatology clinic evaluated the real-world use of clascoterone cream 1% in 10 patients with acne vulgaris, ranging from mild to severe. The study found that clascoterone cream, a topical androgen receptor inhibitor, effectively reduced acne severity over time, demonstrating its efficacy and favorable safety profile for patients aged 12 and older. The cream's versatility is highlighted as it can be used alone or with other treatments, helping to mitigate side effects and prevent acne relapse. Additionally, clascoterone shows promise in treating other dermatological conditions, indicating its broader potential in dermatology.